In thoracic cancers, common genes regulated by prognosis-alternative miRNAs such as BCL2, EGFR, IGF1R, VEGFA, and MET were validated as drug targets and the combination of docetaxel targeted MET and vandetanib targeted VEGFA was illustrated to be effective for non-small cell lung cancer in the clinical trial phase 3 (Liu Y. et al., 2014). The gene discussed is BCL2; the disease is thoracic cancer.